Your session is about to expire
← Back to Search
Topical Immunomodulator
Eucrisa for Eczema
Phase 1
Waitlist Available
Led By Lindsay C Strowd, MD, FAAD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male or female subjects age 2-64
The ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Study Summary
This trial is designed to study a medication for atopic dermatitis. The study will monitor how often the medication is used to help determine how well it works.
Who is the study for?
This trial is for males and females aged 2-64 with mild to moderate atopic dermatitis covering 5% or more of their body. Participants must be able to follow the study procedures, provide consent, and not be using certain other treatments or have conditions that would increase risk.Check my eligibility
What is being tested?
The effectiveness of Eucrisa (crisaborole) ointment in treating atopic dermatitis is being tested. Patients will apply it twice daily for a year, with usage monitored by special caps on the tubes. An online survey aims to improve adherence.See study design
What are the potential side effects?
While specific side effects are not listed here, common ones associated with topical treatments like Eucrisa may include skin irritation, burning or stinging upon application, and possible allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between the ages of 2 and 64.
Select...
I can follow the study's procedures and attend all visits.
Select...
My skin condition covers 5% or more of my body, including possibly my face and genital areas.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adherence to topical Therapy
Secondary outcome measures
Adherence to topical therapy #1
Therapeutic procedure
Adherence to topical therapy #3
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 2 - Online Treatment ResponseExperimental Treatment2 Interventions
Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
Group II: Arm 1 - Standard of CareActive Control1 Intervention
Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
Find a Location
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor
1,231 Previous Clinical Trials
1,001,785 Total Patients Enrolled
6 Trials studying Eczema
618 Patients Enrolled for Eczema
Lindsay C Strowd, MD, FAADPrincipal InvestigatorWake Forest University Health Sciences
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't used systemic therapy for eczema in the last 4 weeks.I can follow the study's procedures and attend all visits.I haven't used prescription skin creams for eczema in the last 2 weeks.I am between the ages of 2 and 64.My skin condition covers 5% or more of my body, including possibly my face and genital areas.You are allergic to crisaborole or any ingredients in the medication.
Research Study Groups:
This trial has the following groups:- Group 1: Arm 1 - Standard of Care
- Group 2: Arm 2 - Online Treatment Response
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger